Corbus Pharmaceuticals Holdings Inc CRBP 深 滬
等待開盤 09-24 09:30:00 美东时间
7.74
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 7.74
- 總市值 1.50亿
- 52周最高 20.56
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 6.325
- 委 比 0.00%
- 總股本 1934.13万
- 歷史最高 323.40
- 量 比 0
- 振 幅 0.00%
- 歷史最低 3.00
- 每 手 1
- 風險率 2.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CNR1（CB1）：曾因"自杀风险"沉寂，如今重回减重赛道
（来源：药研网） 利莫那班退市之后，CB1沉寂了近二十年。如今，这个靶点上有了新进展。 2008年，赛诺菲的利莫那班（rimonabant，商品名Acompl...
今天 13:44
期权扫描 | 豪赌冲上700美元！Meta期权成交较90日翻倍；SpaceX下周开启第14次试飞，资金激战150美元关口
豪赌冲上700美元！Meta期权成交较90日翻倍；SpaceX下周开启第14次试飞，资金激战150美元关口>>
09-16 15:50
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Corbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'
Clinical-stage biopharmaceutical firm Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) on Monday reported topline results from its CANYON-1 Phase 1b trial evaluating CRB-913 as an obesity treatment. The trial demonstrated significant weight loss and a favorable safety profile, paving the way for ...
09-14 22:49
Corbus Reports Positive Phase 1b Results for CRB-913
Corbus Pharmaceuticals ( ($CRBP) ) has issued an update. On September 14, 2026,...
09-14 19:27
Market-Moving News for September 14th
GLW: -8% | Corning shares are trading lower after the company announced a $2 billion offering. ELMT: 49% | Elmet Group Lands $450M US Government Investment To Expand Tungsten Manufacturing, To Invest More Than $165M Across Maine, Michigan And Ohio With Federal Backing CRBP: 25% | Corbus Pharmace...
09-14 19:21
美股夜盘 | Corbus Pharmaceuticals Holdings Inc暴升25.86%，最新股价10.22美元
Corbus Pharmaceuticals Holdings Inc暴升25.86%，报10.22美元
09-14 08:22
Corbus Pharmaceuticals To Report Topline CANYON-1 Obesity Trial Data For CRB-913; Management Team Will Host A Conference Call Webcast On Monday, September 14 At 8:00 a.m. EDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANY...
09-12 04:02
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Corbus Pharmaceuticals will host a virtual webcast on September 14, 2026, at 8:00 AM EDT, to discuss Phase 1b data for CRB-913, a potential obesity treatment. CRB-913 is a once-daily, peripherally restricted CB1 inverse agonist offering a new approach to weight management beyond GLP-1 therapies. The CANYON-1 trial involved 240 obese adults across three doses (20 mg, 40 mg, 60 mg) with a 12-week treatment and 4-week follow-up. Harold Bays, M.D., a...
09-11 20:01
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals Holdings, Inc. granted inducement equity awards, including stock options and restricted stock units, to Leonardo Nicacio upon his appointment as Chief Medical Officer. The awards consist of options to purchase 191,676 shares with a $10.09 exercise price and 58,333 restricted stock units, both vesting over four years. The company focuses on developing therapies in oncology and obesity.
08-17 14:00
